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Abstract
Background: Charcot osteoarthropathy or charcot foot is a rare, chronic, non-communicable condition of bones and
joints which may results into severe deformity and more prone to develop ulcers possibly leading to amputation. The
purpose of this study was to determine the prevalence of Charcot osteoarthropathy and its association with age, BMI,
gender, duration of diabetes, HBA1c and peripheral neuropathy.
Methods: A total of 1931 subjects with type 2 diabetes having mean age 50.72 ± 10.66 years presenting in a specialist
diabetes clinic at shalamar hospital, Lahore, Pakistan were enrolled. The diagnosis of Charcot osteoarthropathy was
made by examination of both dorsal and plantar surfaces of foot for swelling, erythema, increase in temperature and
any musculoskeletal deformity which was later confirmed by radiographs. Assessment of neuropathy was carried out
by checking the sense of pressure, joint position and vibration. BMI (Body Mass Index), fasting blood glucose (FBG) and
HbA1C were determined.
Results: In all subjects including male 704 (36.45 %) and female 1227 (63.55 %), 0.4 % subjects had charcot deformity,
while 0.2 %, 0.15 % and 0.05 % subjects having right, left and bilateral deformity respectively. Bilaterally symmetrical
neuropathy was diagnosed in 25.4 % in subjects. There was a significant association (p < 0.05) of deformity with
duration of diabetes, HbA1C and neuropathy, however no significant association (p > 0.05) was found with age, BMI,
weight, height and gender.
Conclusion: There is a need to have a special care of persons with diabetes regarding blood glucose control and
development of peripheral neuropathy. Early identification and management of risk factors may prevent the
occurrence of charcot deformity. Patients must be educated about the foot care.
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Background
Diabetes is a chronic condition associated with the num-
ber of complications such as peripheral artery disease, foot
ulcerations, peripheral neuropathy and charcot osteoar-
thropathy. These complications are expected to increase
in the prevalence [1] as the worldwide prevalence of dia-
betes for all age groups is expected to be 4.4 % by 2030
which was approximately 2.8 % in the year 2000 [2]. In
Pakistan, according to the International Diabetes Feder-
ation (IDF) the prevalence of diabetes is quite high, about
6.7 million of the population has diabetes. By the year
2035, which is likely to increase to 12.8 million [3].
Charcot osteoarthropathy is a most overlooked serious
limb-threatening complication of diabetes mellitus.
Charcot foot was first described in 1883, and it was asso-
ciated to diabetes mellitus in 1936 [4]. It is a chronic
progressive noncommunicable disease of the joints and
bones which may involve single or multiple bones or
joints. It is characterized by painless swelling in the feet
and ankles along with damage in bones and joints. It can
lead to deformity of bone and joint due to underlying
neuropathy, trauma or any disturbance in bone metabol-
ism [5]. The classic deformity associated with Charcot
foot is “rocker bottom deformity” which is a collapse of
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midfoot [6]. Charcot osteoarthropathy occurs mostly in
persons with diabetes with severe peripheral neuropathy
[7, 8]. The prevalence of Charcot osteoarthropathy is re-
ported to be 0.08 % to 13 % in individual with diabetes
and high risk patients respectively [7].
Foot complications are now considered to be the most
common cause of hospital admission and lower limb
amputation in subjects with diabetes. The diagnosis of
charcot foot is not easy and is problematic even for the
very experienced practitioners. Its diagnosis in early
stages is extremely difficult and many cases of charcot
foot are misdiagnosed. The actual prevalence may be
higher due to delay in diagnosis or misdiagnosis [9].
X-rays plays a major role in diagnosis of charcot foot
and helps in distinguishing it from osteomyelitis. Other
imaging techniques such as CT Scan, MRI and PET scan
can also be used to diagnose charcot foot [4].
The aim of the study was to determine the prevalence
of Charcot foot and its association with age, gender, dur-




It was a cross sectional study including a total of 1931
(mean age 50.72 ± 10.66) type 2 diabetes persons including
both male and female presenting in Sakina Institute of
Diabetes & Endocrine Research (SiDER) which is a spe-
cialist diabetes clinic at Shalamar Institute of Health Sci-
ences, Lahore, Pakistan, over period of one year from Sept
2012 to August 2013. The cognitive impaired subjects
were excluded from the study. The demographic informa-
tion (name, age, sex, address, education, duration of dia-
betes) was collected from customized designed hospital
based software. Data entry was done by a trained doctor
proficient in using the software. The maintenance of data
and software was done by hospital IT department. The
Ethical Review Committee of Shalamar Institute of Health
Sciences reviewed and approved the study. The diabetic
condition was confirmed by review of medical record, pre-
vious laboratory tests. The patients having fasting blood
glucose ≥126 mg/dl were considered as diabetic. The writ-
ten informed consent was taken after explaining the na-
ture of the study to the patients.
Examination
Complete general physical and systemic examination
was carried out. Examination of the arterial pulse in dor-
salis pedis and posterior tibial arteries were palpated and
compared bilaterally.
Charcot osteoarthropathy
Physical examination of the lower limb was carried out;
diagnosis of Charcot osteoarthropathy of foot was
primarily based on history and clinical examination.
Both dorsal and plantar surfaces of the foot were exam-
ined for swelling, erythema, increase in temperature and
any musculoskeletal deformity which were later on con-
firmed by X-rays.
Body height and weight
The standard procedure was followed to measure body
weight and height. Body weight was measured using a
digital scale whereas a wall-mounted stadiometer was
used to measure body height. Then, BMI of each subject
was calculated.
Assessment for neuropathy
The examination of the patients was done for the presence
of neuropathy, the sense of pressure, joint position and vi-
bration were checked with the standard method and each
test was performed three times. 128 Hz tuning fork was
used to check the sense of vibration by taking halluces as
standard point, if the subject felt the vibration it was con-
sidered as positive and if the subject failed to perceive the
vibration sensation while the person examining still felt,
test was recorded as negative. The vibration sense was
considered as impaired if two out of three times the sub-
ject was unable to perceive the vibration.
The sense of position was checked according to the
standard clinical practice which is dorsal flexion and
plantar flexion at interphalangeal joint. The interphalan-
geal joint of the big toe was flexed for 100 in upward
and downward direction and the subject was asked to
tell the position of the joint.
The loss of proper proprioception is documented if
the patient could not identify the right direction of the
big toe. The test was performed three times, if the pa-
tient could not identify the position two out of three
times the test was considered impaired.
Semmes-Weinstein (SW) monofilament (10gm) was
used to check the pressure sensation of the persons at
four sites namely 1st, 3rd, and 5th metatarsal heads and
plantar surface of distal hallux as recommended by
Boulton A J et al. [10]. The pressure was applied with
10 g monofilament perpendicular to the above men-
tioned sites for 2 seconds at least and the persons were
asked to nod their head or say ‘yes’ when they felt the
monofilament. The test was reported as abnormal if patient
is unable to perceive the sensation two out of three times.
Abnormal test is considered as impairment of sensation.
Analytical determinations
The sample of 4 ml of venous blood was collected from
the cubital vein after overnight fasting of 12 h. All pa-
rameters and were recorded in duplicate. Standard pro-
cedures were followed to determine the parameters. The
commercial reagent kit (ACON Laboratories, San Diego,
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California, USA) was used to measure fasting blood glu-
cose levels by the glucose oxidase method. HbA1-c was
estimated by high affinity liquid chromatography with a
D-SI Glycomat (Provalis Diagnostics, Deeside, UK).
Statistical analysis
SPSS (Statistical Package for Social Sciences) version 17.0
[SPSS, Inc. Chicago, IL, USA] was used to enter and
analyze data. The Quantitative variables were expressed as
mean ± standard deviation (S.D), whereas qualitative data
was presented by frequency and percentages.
The Kruskal Wallis test was applied to determine asso-
ciation of age, BMI, HbA1c, duration of diabetes for de-
formity. A p-value of < 0.05 was considered statistically
significant.
Results
Characteristics of study population
A total of 1931 type 2 persons with diabetes, including
male 704 (36.45 %) and female 1227 (63.55 %) were re-
cruited. The mean age was 50 ± 10.66 years with the
duration of diabetes 7.16 ± 6.28 years. The sample popu-
lation has mean BMI of 23.26 ± 4.59 kg/m2. The charac-
teristics of study population are given in Table 1.
Charcot osteoarthropathy
A total of 1931 subjects were examined for charcot de-
formity. In 99.6 % of the subjects, no deformity was found
while 0.4 % of the subjects had the deformity. When these
subjects were further evaluated, 0.15 % of the all subjects
and 37.5 % of affected subjects had the charcot deformity
of right foot while 0.2 % of all subjects and 50 % of af-
fected individuals had the deformity of left foot. In 0.05 %
among whole sample population and 12.5 % of reported
charcot had the bilateral deformity as shown in Table 2.
The significant association of charcot osteoarthropathy
was observed with duration of diabetes (χ2 = 4.37, p =
0.036), neuropathy (χ2 = 4.017, p = 0.045) and HbA1c (χ2 =
9.081, p = 0.003) respectively with their mean rank shown
in the Table 3, whereas no association was found with BMI
(χ2 = 0.05, p = 0.036), gender (χ2 = 2.35,1 p = 0.125), height
(χ2 = 1.345, p = 0.246), weight (χ2 = 0.001, p = 0.971,) and
age (χ2 = 2.11, p = 0.146). The data was stratified into differ-
ent age groups and it was found that age group of 60-79
years shared the 50 % (n = 4) burden of deformity found as
given in Table 4.
Neuropathy
All the subjects were examined for neuropathy. It was
found that bilaterally symmetrical peripheral neuropathy
was present in 25.6 % in subjects.
Table 1 Characteristics of study population
Parameters
Total Sample population (n) 1931
Age (years) 50.72 ± 10.66
Gender
Male (%) 704(36.45 %)
Female (%) 1227(63.55 %)
Duration of Diabetes (years) 7.16 ± 6.28
Body weight (Kg) 73.80 ± 15.1
Body Height (cm) 158 ± 10.7
BMI (kg/m2) 23.26 ± 4.59
HbA1C (%) 9.61 ± 2.19
Data are expressed as mean ± SD and frequencies
Table 2 Charcot osteoarthropathy in persons with diabetes
Characteristics Number Percentage
Total sample population 1931 100 %
Deformity absent 1923 99.6 %
Deformity present 8 0.4 %
Deformity of right foot 3 0.15 %
Deformity of left foot 4 0.2 %
Bilateral deformity 1 0.05 %
Data are expressed as frequencies and percentage
Table 3 Mean Rank of Charcot Osteoarthropathy in people with
diabetes
With Charcot Without Charcot χ2/ P-value
osteoarthropathy osteoarthropathy
(n = 8) (n = 1923)
Age 964.81 1251.12 2.11/0.146
Body weight 966.03 958.75 0.001/0.971
Height 965.05 1194.00 1.34/0.246




HbA1C 405.03 656.75 9.08/0.003*
kruskul-Wallis test. p* < 0.05 was considered statistically significant
Table 4 Prevalence of Charcot osteoarthropathy in different
age group
Age groups No deformity Deformity
(years) n = 1923 n = 8
n % n %
<35 92 4.7 0 0
35 - 44 402 20.8 2 0.1
45 - 59 974 50.4 2 0.1
60 - 79 441 22.8 4 0.2
>79 14 0.72 0 0
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Discussion
Presently, the most common cause of osteoarthropathy
is diabetes over the world [11–15] and prevalence of dia-
betes is increasing worldwide [3]. The prevalence of
charcot osteoarthropathy was found to be 0.4 % in sub-
jects with diabetes in the current study, however previ-
ous data reported 0.08-7.5 % prevalence [16].
Charcot osteoarthropathy is present in unilateral
limb in most cases but it can be present in bilateral
limbs [17, 18]. Bilateral deformity was observed in
12.5 % of the reported cases of charcot osteoarthropa-
thy in the present study, which is similar to the preva-
lence of 9 % and 12 % of the persons with diabetes in
previous studies [19, 20].
Neuropathy was observed in 25.6 % of the population
studied in the current study, whereas 28 % of persons
with neuropathy was reported in european diabetes
centre study of complication [21] while a study reported
42.1 % of the persons had sensory neuropathy and 2 %
of them had Charcot osteoarthropathy [22]. However,
the concomitant presence of deformity and peripheral
neuropathy significantly increase the chances of skin ul-
ceration and lower limb amputation [18].
There was no gender related differences observed in
relation to charcot osteoarthropathy in the present
study. Whereas a study has indicated that men and
women are equally affected with charcot osteoarthropa-
thy [23]. Stuck and colleagues suggested that the obesity
is also a predisposing factor for charcot osteoarthropathy
in european population [24]. In contrast to this, we
failed to find any significant association of charcot
osteoarthropathy with BMI. This difference might be
due to regional, ethnic or due to difference in sample
size and statistical methods used.
Deformity is associated with duration of diabetes
and HbA1C in the current study. Likewise, Charcot
osteoarthropathy has been associated with longstand-
ing duration of diabetes and neuropathy in previous
studies [24, 25]. As far as age is concerned, the highest
prevalence of deformity has been reported in age
group of more than 60 years [24]. Our study also re-
ported more prevalence in more than 60 years old
individuals.
It has been observed that neuropathy in the presence
of deformity or limited joint mobility results in 12.1
times higher risk of foot problems, whereas patients
who had ulcer or amputation done in the past have a
36.4 times higher risk for developing another ulcer
[26], it might be linked to superimposed infection be-
cause such persons are more likely to develop recurrent
ulcers.
This condition is more focused now because it is not
only the cause of chronic progressive deformity but also
intensifies the likelihood of major amputation [27].
Conclusion
Although the prevalence of charcot osteoarthropathy in
this sample population is relatively low, but it has poten-
tial risks such as permanent disability, amputation and
recurrent ulcers. It was found that neuropathy, HbA1c
and duration of diabetes are predisposing risk factors for
charcot osteoarthropathy while age, gender and BMI are
not significant risk factors.
The earlier diagnosis, timely appropriate treatment may
help in avoiding severe, irreversible disability and deform-
ity, which can be done with the tool of patient education
and conducting seminar to increase awareness.
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